Skip to main content

FRA:TEV - Teva Pharmaceutical Industries Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
€0.00
This price target is based on 0 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a NaN upside from the last price of €0.00.

N/A

The current consensus among 0 investment analysts is to n/a stock in Teva Pharmaceutical Industries. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/8/2019GMP SecuritiesReiterated RatingBuy$11.00
i
1/7/2019TD SecuritiesReiterated RatingBuy$10.00
i
(Data available from 5/16/2016 forward)
Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

The following Wall Street research analysts have issued stock ratings on Teva Pharmaceutical Industries in the last year:
View the latest analyst ratings for TEV.

What is the current price target for Teva Pharmaceutical Industries?

0 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEV.

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TEV.

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?

The company's listed phone number is 972 3 914 8171. The official website for Teva Pharmaceutical Industries is www.tevapharm.com.